You have 9 free searches left this month | for more free features.

Cetuximab

Showing 1 - 25 of 1,156

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Colorectal Cancer Trial (Cetuximab + Envafolimab + mFOLFOXIRI, Cetuximab + mFOLFOX6/FOLFIRI)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab + Envafolimab + mFOLFOXIRI
  • Cetuximab + mFOLFOX6/FOLFIRI
  • (no location specified)
Jul 24, 2023

Locally Advanced Hypopharyngeal Carcinoma Trial in Shanghai (drug, procedure, radiation)

Not yet recruiting
  • Locally Advanced Hypopharyngeal Carcinoma
  • three cycles (toripalimab + cetuximab + platinum)
  • +2 more
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 22, 2023

Metastatic Colorectal Cancer, Cetuximab, Skin Toxicity Trial in Guangzhou (Crisaborole Ointment, Cetuximab)

Recruiting
  • Metastatic Colorectal Cancer
  • +2 more
  • Crisaborole Ointment
  • Cetuximab
  • Guangzhou, Guangdong, China
    WeiWei Xiao
Nov 3, 2023

Squamous Cell Carcinoma of the Head and Neck Trial (Xevinapant, Placebo, cetuximab)

Not yet recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • (no location specified)
Jul 3, 2023

Metastatic Colorectal Cancer Trial in Houston (Cetuximab, Ulixertinib, Encorafenib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

Metastatic Colorectal Cancer Trial (Cetuximab and irinotecan)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab and irinotecan
  • (no location specified)
Jul 26, 2023

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +2 more
  • BET Bromodomain Inhibitor ZEN-3694
  • +6 more
  • (no location specified)
Oct 25, 2023

Colorectal Cancer Liver Metastases Trial in Shanghai (Cetuximab)

Not yet recruiting
  • Colorectal Cancer Liver Metastases
  • Cetuximab
  • Shanghai, Shanghai, China
  • +1 more
May 22, 2023

Colorectal Cancer, Liver Metastases Trial in Shanghai (mFOLFOX6 + Cetuximab, mFOLFOX 6)

Not yet recruiting
  • Colorectal Cancer
  • Liver Metastases
  • mFOLFOX6 + Cetuximab
  • mFOLFOX 6
  • Shanghai, China
    Zhongshan hosptial, Fudan University
Jul 14, 2023

Lung Cancer, Video-assisted Thoracic Surgery, EGFR Trial in Torino (Cetuximab-IRDye800)

Not yet recruiting
  • Lung Cancer
  • +3 more
  • Torino, TO, Italy
    Azienda Ospedaliera Universitaria Città della Salute e della Sci
Oct 23, 2023

Glioblastoma, High-grade Glioma Trial in Groningen (Cetuximab-IRDye800)

Recruiting
  • Glioblastoma
  • High-grade Glioma
  • Groningen, Netherlands
    UMCG
Jun 26, 2023

Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Trial in Guangzhou (Cetuximab, Zimberelimab, Docetaxel)

Not yet recruiting
  • Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
  • Cetuximab
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University
Oct 24, 2023

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Squamous Cell Carcinoma of Head and Neck Trial in Hangzhou (Toripalimab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Hangzhou, Zhejiang, China
    Department of Medical Onocology, First Affiliated Hospital of Zh
Oct 7, 2023

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in

Not yet recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +2 more
  • Cetuximab
  • +2 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Oct 2, 2023

Colorectal Cancer Trial (Tislelizumab, Irinotecan Hydrochloride, cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • (no location specified)
Mar 23, 2023

Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Trial in Wuhan (drug, procedure, radiation)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Neoadjuvant Therapy
  • 3cycles (Toripalimab + cetuximab)
  • +2 more
  • Wuhan, Hebei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 6, 2023

Advance NSCLC Trial (GFH925, Cetuximab)

Not yet recruiting
  • Advance Non-small Cell Lung Cancer
  • (no location specified)
Mar 7, 2023

Metastatic Colorectal Cancer Trial in Guangzhou (Cetuximab, Capecitabine)

Recruiting
  • Metastatic Colorectal Cancer
  • Guangzhou, Guangdong, China
    The Sixth Affiliated Hospital of Sun Yat-sen University
Mar 7, 2023

Advanced or Metastatic Squamous NSCLC Trial in Sydney (HMBD-001, Docetaxel, Cetuximab)

Not yet recruiting
  • Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  • Sydney, New South Wales, Australia
    GenesisCare North Shore
Jun 20, 2023

Cancer of Colon Trial in Jerusalem (Cetuximab)

Terminated
  • Cancer of Colon
  • Cetuximab
  • Jerusalem, Israel
    Hadassah Ein Kerem
Aug 2, 2022

Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8 Trial (drug, biological, procedure,

Not yet recruiting
  • Colon Adenocarcinoma
  • +4 more
  • (no location specified)
Jan 24, 2023

Colon Cancer, Colorectal Cancer Trial in Houston (MRTX849, Irinotecan, Cetuximab)

Not yet recruiting
  • Colon Cancer
  • Colorectal Cancer
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2023